"4"^^ . . "Immunomodulation therapy - lenalidomide in the treatment of myelodysplastic syndrome in low-risk groups with deletion of the long arm of chromosome 5"@en . "Jon\u00E1\u0161ov\u00E1, Anna" . "Imunomodula\u010Dn\u00ED terapie - lenalidomid v l\u00E9\u010Db\u011B myelodysplastick\u00E9ho syndromu n\u00EDzce rizikov\u00FDch skupin s delec\u00ED dlouh\u00E9ho ram\u00E9nka 5. chromosomu"@cs . "[A0900E6A3001]" . . . "Immunomodulation therapy is used to treat the cytogenetically most common subgroups of patients with MDS, specifically patients with the deletion of the long arm of chromosome 5, and is particularly effective in anaemic patients with 5q-syndrome. Lenalidomide is a thalidomide analogue with greater effect and without typical undesirable effects. Its efficacy and safety has been confirmed in clinical studies, and we look back to our own experience in this indication."@en . "1"^^ . . . "lenalidomide; 5q-syndrome; myelodysplastic syndrome"@en . "Imunomodula\u010Dn\u00ED terapie - lenalidomid v l\u00E9\u010Db\u011B myelodysplastick\u00E9ho syndromu n\u00EDzce rizikov\u00FDch skupin s delec\u00ED dlouh\u00E9ho ram\u00E9nka 5. chromosomu" . "Immunomodulation therapy - lenalidomide in the treatment of myelodysplastic syndrome in low-risk groups with deletion of the long arm of chromosome 5"@en . "9" . "5" . "1"^^ . "1801-1209" . "79363" . "RIV/00064165:_____/13:10195508" . "CZ - \u010Cesk\u00E1 republika" . "RIV/00064165:_____/13:10195508!RIV14-MZ0-00064165" . "Imunomodula\u010Dn\u00ED terapie se pou\u017E\u00EDv\u00E1 v l\u00E9\u010Db\u011B cytogeneticky nej\u010Dast\u011Bj\u0161\u00ED podskupiny nemocn\u00FDch s MDS, a to nemocn\u00FDch s delec\u00ED dlouh\u00E9ho ram\u00E9nka 5. chromosomu, zvl\u00E1\u0161t\u011B \u00FA\u010Dinn\u00E1 je u anemick\u00FDch pacient\u016F s 5q-syndromem. Lenalidomid je analog thalidomidu s v\u011Bt\u0161\u00EDm \u00FA\u010Dinkem, ale bez typick\u00FDch ne\u017E\u00E1douc\u00EDch \u00FA\u010Dink\u016F. Jeho \u00FA\u010Dinnost a bezpe\u010Dnost byla potvrzena v klinick\u00FDch studi\u00EDch, m\u00E1me k dispozici i na\u0161e vlastn\u00ED zku\u0161enosti v t\u00E9to indikaci." . . "Imunomodula\u010Dn\u00ED terapie - lenalidomid v l\u00E9\u010Db\u011B myelodysplastick\u00E9ho syndromu n\u00EDzce rizikov\u00FDch skupin s delec\u00ED dlouh\u00E9ho ram\u00E9nka 5. chromosomu"@cs . "V" . . . "Farmakoterapie" . . "Imunomodula\u010Dn\u00ED terapie - lenalidomid v l\u00E9\u010Db\u011B myelodysplastick\u00E9ho syndromu n\u00EDzce rizikov\u00FDch skupin s delec\u00ED dlouh\u00E9ho ram\u00E9nka 5. chromosomu" . . . . "Imunomodula\u010Dn\u00ED terapie se pou\u017E\u00EDv\u00E1 v l\u00E9\u010Db\u011B cytogeneticky nej\u010Dast\u011Bj\u0161\u00ED podskupiny nemocn\u00FDch s MDS, a to nemocn\u00FDch s delec\u00ED dlouh\u00E9ho ram\u00E9nka 5. chromosomu, zvl\u00E1\u0161t\u011B \u00FA\u010Dinn\u00E1 je u anemick\u00FDch pacient\u016F s 5q-syndromem. Lenalidomid je analog thalidomidu s v\u011Bt\u0161\u00EDm \u00FA\u010Dinkem, ale bez typick\u00FDch ne\u017E\u00E1douc\u00EDch \u00FA\u010Dink\u016F. Jeho \u00FA\u010Dinnost a bezpe\u010Dnost byla potvrzena v klinick\u00FDch studi\u00EDch, m\u00E1me k dispozici i na\u0161e vlastn\u00ED zku\u0161enosti v t\u00E9to indikaci."@cs . . . .